[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$ftO6MObny80m7LzaXAh7KcUqbdROuYYEmq4YASGERF6w":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":33,"phaseBuckets":73,"rows":80},"Semmelweis University",[4,6],"Semmelweis University Heart and Vascular Center",153,false,47,7,67802,17,123,[15,18,20,22,25,27,29,31],{"name":16,"count":17},"Coronary Artery Disease",4,{"name":19,"count":17},"Oral Soft Tissue Conditions",{"name":21,"count":17},"Endometriosis",{"name":23,"count":24},"Vitamin D Deficiency",3,{"name":26,"count":24},"Alveolar Bone Loss",{"name":28,"count":24},"Perinatal Asphyxia",{"name":30,"count":24},"Chronic Heart Failure",{"name":32,"count":24},"Cardiac Surgery",[34,39,44,49,54,59,64,68],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT06454084","Investigation of Endothelium-dependent Vasodilation in Human Gingiva","2024-12-31","Acetylcholine Chloride",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT06747260","Feasibility and Safety of Intranasally Administered Breast Milk in HIE","2025-09-22","Intranasal breast milk",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT05889390","Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer","2025-10-31","Paclitaxel",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT07030855","Efficacy of Elixirium Thymi Compositum in the Treatment of Acute Bronchitis in Pediatric Patients","2027-06","Elixirium thymi compositum",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT05836610","Hydrocortisone Therapy Optimization During Hypothermia Treatment in Asphyxiated Neonates","2027-09","Hydrocortisone",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT06401083","The Effect of an Additional Pre-extubational Loading Dose of Caffeine-citrate","2027-12","Caffeine citrate",{"nctId":65,"briefTitle":66,"date":67,"intervention":43},"NCT06746532","Intranasal Breast Milk Therapy in HIE","2028-01",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT07484633","A Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients","2028-04","Extended infusion time of the following beta-lactam: meropenem",[74,75,76,77,78,79],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[81,120,143,161,185,218,236,254,272,290,308,326,344,369,387,405,440,461,490,517,542,598,624,650,668,692,731,757,783,809,836,860,885,903,928,955],{"intervention":58,"totalTrials":82,"cells":83},2,{"EARLY_PHASE1":84,"PHASE1":87,"PHASE2":89,"PHASE3":91,"PHASE4":106,"NA":118},{"trials":85,"activeCount":86},[],0,{"trials":88,"activeCount":86},[],{"trials":90,"activeCount":86},[],{"trials":92,"activeCount":86},[93],{"nctId":94,"briefTitle":95,"status":96,"phases":97,"primaryCompletion":98,"completion":99,"start":100,"enrollment":101,"conditions":102,"interventions":105},"NCT02700828","Hydrocortisone Treatment In Systemic Low Blood Pressure During Hypothermia in Asphyxiated Newborns","COMPLETED",[76,77],"2017-11","2022-12-15","2016-02",32,[103,104],"Hypoxic-Ischemic Encephalopathy","Asphyxia",[58],{"trials":107,"activeCount":117,"soonestReadout":57},[108],{"nctId":55,"briefTitle":56,"status":109,"phases":110,"primaryCompletion":57,"completion":57,"start":111,"enrollment":112,"conditions":113,"interventions":116},"RECRUITING",[78],"2021-09-21",50,[103,104,114,115],"Hypotension","Circulatory Failure Neonatal",[58],1,{"trials":119,"activeCount":86},[],{"intervention":53,"totalTrials":117,"cells":121},{"EARLY_PHASE1":122,"PHASE1":124,"PHASE2":126,"PHASE3":128,"PHASE4":130,"NA":141},{"trials":123,"activeCount":86},[],{"trials":125,"activeCount":86},[],{"trials":127,"activeCount":86},[],{"trials":129,"activeCount":86},[],{"trials":131,"activeCount":117,"soonestReadout":52},[132],{"nctId":50,"briefTitle":51,"status":133,"phases":134,"primaryCompletion":52,"completion":62,"start":135,"enrollment":136,"conditions":137,"interventions":139},"ENROLLING_BY_INVITATION",[78],"2025-07",56,[138],"Acute Bronchitis",[53,140],"Elixirium thymi compositum (FoNo VIII.) placebo",{"trials":142,"activeCount":86},[],{"intervention":140,"totalTrials":117,"cells":144},{"EARLY_PHASE1":145,"PHASE1":147,"PHASE2":149,"PHASE3":151,"PHASE4":153,"NA":159},{"trials":146,"activeCount":86},[],{"trials":148,"activeCount":86},[],{"trials":150,"activeCount":86},[],{"trials":152,"activeCount":86},[],{"trials":154,"activeCount":117,"soonestReadout":52},[155],{"nctId":50,"briefTitle":51,"status":133,"phases":156,"primaryCompletion":52,"completion":62,"start":135,"enrollment":136,"conditions":157,"interventions":158},[78],[138],[53,140],{"trials":160,"activeCount":86},[],{"intervention":63,"totalTrials":117,"cells":162},{"EARLY_PHASE1":163,"PHASE1":165,"PHASE2":167,"PHASE3":169,"PHASE4":171,"NA":183},{"trials":164,"activeCount":86},[],{"trials":166,"activeCount":86},[],{"trials":168,"activeCount":86},[],{"trials":170,"activeCount":86},[],{"trials":172,"activeCount":117,"soonestReadout":62},[173],{"nctId":60,"briefTitle":61,"status":109,"phases":174,"primaryCompletion":62,"completion":175,"start":176,"enrollment":177,"conditions":178,"interventions":182},[78],"2028-12","2023-12-21",226,[179,180,181],"Apnea of Prematurity","Premature Birth","Respiratory Failure",[63],{"trials":184,"activeCount":86},[],{"intervention":72,"totalTrials":117,"cells":186},{"EARLY_PHASE1":187,"PHASE1":189,"PHASE2":191,"PHASE3":193,"PHASE4":195,"NA":216},{"trials":188,"activeCount":86},[],{"trials":190,"activeCount":86},[],{"trials":192,"activeCount":86},[],{"trials":194,"activeCount":86},[],{"trials":196,"activeCount":117,"soonestReadout":71},[197],{"nctId":69,"briefTitle":70,"status":198,"phases":199,"primaryCompletion":71,"completion":71,"start":200,"enrollment":201,"conditions":202,"interventions":208},"NOT_YET_RECRUITING",[78],"2026-04",110,[203,204,205,206,207],"Infection","Sepsis","NICU","PICU","Beta Lactams",[72,209,210,211,212,213,214,215],"Short-term infusion time of the following beta-lactam: meropenem","Extended infusion time of the following beta-lactam: piperacillin\u002Ftazobactam","Extended infusion time of the following beta-lactam: cefepime","Extended infusion time of the following beta-lactam: ceftriaxone","Short-term infusion time of the following beta-lactam: piperacillin\u002Ftazobactam","Short-term infusion time of the following beta-lactam: cefepime","Short-term infusion time of the following beta-lactam: ceftriaxone",{"trials":217,"activeCount":86},[],{"intervention":209,"totalTrials":117,"cells":219},{"EARLY_PHASE1":220,"PHASE1":222,"PHASE2":224,"PHASE3":226,"PHASE4":228,"NA":234},{"trials":221,"activeCount":86},[],{"trials":223,"activeCount":86},[],{"trials":225,"activeCount":86},[],{"trials":227,"activeCount":86},[],{"trials":229,"activeCount":117,"soonestReadout":71},[230],{"nctId":69,"briefTitle":70,"status":198,"phases":231,"primaryCompletion":71,"completion":71,"start":200,"enrollment":201,"conditions":232,"interventions":233},[78],[203,204,205,206,207],[72,209,210,211,212,213,214,215],{"trials":235,"activeCount":86},[],{"intervention":210,"totalTrials":117,"cells":237},{"EARLY_PHASE1":238,"PHASE1":240,"PHASE2":242,"PHASE3":244,"PHASE4":246,"NA":252},{"trials":239,"activeCount":86},[],{"trials":241,"activeCount":86},[],{"trials":243,"activeCount":86},[],{"trials":245,"activeCount":86},[],{"trials":247,"activeCount":117,"soonestReadout":71},[248],{"nctId":69,"briefTitle":70,"status":198,"phases":249,"primaryCompletion":71,"completion":71,"start":200,"enrollment":201,"conditions":250,"interventions":251},[78],[203,204,205,206,207],[72,209,210,211,212,213,214,215],{"trials":253,"activeCount":86},[],{"intervention":211,"totalTrials":117,"cells":255},{"EARLY_PHASE1":256,"PHASE1":258,"PHASE2":260,"PHASE3":262,"PHASE4":264,"NA":270},{"trials":257,"activeCount":86},[],{"trials":259,"activeCount":86},[],{"trials":261,"activeCount":86},[],{"trials":263,"activeCount":86},[],{"trials":265,"activeCount":117,"soonestReadout":71},[266],{"nctId":69,"briefTitle":70,"status":198,"phases":267,"primaryCompletion":71,"completion":71,"start":200,"enrollment":201,"conditions":268,"interventions":269},[78],[203,204,205,206,207],[72,209,210,211,212,213,214,215],{"trials":271,"activeCount":86},[],{"intervention":212,"totalTrials":117,"cells":273},{"EARLY_PHASE1":274,"PHASE1":276,"PHASE2":278,"PHASE3":280,"PHASE4":282,"NA":288},{"trials":275,"activeCount":86},[],{"trials":277,"activeCount":86},[],{"trials":279,"activeCount":86},[],{"trials":281,"activeCount":86},[],{"trials":283,"activeCount":117,"soonestReadout":71},[284],{"nctId":69,"briefTitle":70,"status":198,"phases":285,"primaryCompletion":71,"completion":71,"start":200,"enrollment":201,"conditions":286,"interventions":287},[78],[203,204,205,206,207],[72,209,210,211,212,213,214,215],{"trials":289,"activeCount":86},[],{"intervention":213,"totalTrials":117,"cells":291},{"EARLY_PHASE1":292,"PHASE1":294,"PHASE2":296,"PHASE3":298,"PHASE4":300,"NA":306},{"trials":293,"activeCount":86},[],{"trials":295,"activeCount":86},[],{"trials":297,"activeCount":86},[],{"trials":299,"activeCount":86},[],{"trials":301,"activeCount":117,"soonestReadout":71},[302],{"nctId":69,"briefTitle":70,"status":198,"phases":303,"primaryCompletion":71,"completion":71,"start":200,"enrollment":201,"conditions":304,"interventions":305},[78],[203,204,205,206,207],[72,209,210,211,212,213,214,215],{"trials":307,"activeCount":86},[],{"intervention":214,"totalTrials":117,"cells":309},{"EARLY_PHASE1":310,"PHASE1":312,"PHASE2":314,"PHASE3":316,"PHASE4":318,"NA":324},{"trials":311,"activeCount":86},[],{"trials":313,"activeCount":86},[],{"trials":315,"activeCount":86},[],{"trials":317,"activeCount":86},[],{"trials":319,"activeCount":117,"soonestReadout":71},[320],{"nctId":69,"briefTitle":70,"status":198,"phases":321,"primaryCompletion":71,"completion":71,"start":200,"enrollment":201,"conditions":322,"interventions":323},[78],[203,204,205,206,207],[72,209,210,211,212,213,214,215],{"trials":325,"activeCount":86},[],{"intervention":215,"totalTrials":117,"cells":327},{"EARLY_PHASE1":328,"PHASE1":330,"PHASE2":332,"PHASE3":334,"PHASE4":336,"NA":342},{"trials":329,"activeCount":86},[],{"trials":331,"activeCount":86},[],{"trials":333,"activeCount":86},[],{"trials":335,"activeCount":86},[],{"trials":337,"activeCount":117,"soonestReadout":71},[338],{"nctId":69,"briefTitle":70,"status":198,"phases":339,"primaryCompletion":71,"completion":71,"start":200,"enrollment":201,"conditions":340,"interventions":341},[78],[203,204,205,206,207],[72,209,210,211,212,213,214,215],{"trials":343,"activeCount":86},[],{"intervention":48,"totalTrials":117,"cells":345},{"EARLY_PHASE1":346,"PHASE1":348,"PHASE2":350,"PHASE3":352,"PHASE4":365,"NA":367},{"trials":347,"activeCount":86},[],{"trials":349,"activeCount":86},[],{"trials":351,"activeCount":86},[],{"trials":353,"activeCount":117,"soonestReadout":47},[354],{"nctId":45,"briefTitle":46,"status":355,"phases":356,"primaryCompletion":47,"completion":357,"start":358,"enrollment":359,"conditions":360,"interventions":362},"ACTIVE_NOT_RECRUITING",[76,77],"2026-12-31","2023-02-20",71,[361],"HER2-negative Breast Cancer",[48,363,364],"Carboplatin","Cyclophosphamide\u002FDoxorubicin",{"trials":366,"activeCount":86},[],{"trials":368,"activeCount":86},[],{"intervention":363,"totalTrials":117,"cells":370},{"EARLY_PHASE1":371,"PHASE1":373,"PHASE2":375,"PHASE3":377,"PHASE4":383,"NA":385},{"trials":372,"activeCount":86},[],{"trials":374,"activeCount":86},[],{"trials":376,"activeCount":86},[],{"trials":378,"activeCount":117,"soonestReadout":47},[379],{"nctId":45,"briefTitle":46,"status":355,"phases":380,"primaryCompletion":47,"completion":357,"start":358,"enrollment":359,"conditions":381,"interventions":382},[76,77],[361],[48,363,364],{"trials":384,"activeCount":86},[],{"trials":386,"activeCount":86},[],{"intervention":364,"totalTrials":117,"cells":388},{"EARLY_PHASE1":389,"PHASE1":391,"PHASE2":393,"PHASE3":395,"PHASE4":401,"NA":403},{"trials":390,"activeCount":86},[],{"trials":392,"activeCount":86},[],{"trials":394,"activeCount":86},[],{"trials":396,"activeCount":117,"soonestReadout":47},[397],{"nctId":45,"briefTitle":46,"status":355,"phases":398,"primaryCompletion":47,"completion":357,"start":358,"enrollment":359,"conditions":399,"interventions":400},[76,77],[361],[48,363,364],{"trials":402,"activeCount":86},[],{"trials":404,"activeCount":86},[],{"intervention":43,"totalTrials":82,"cells":406},{"EARLY_PHASE1":407,"PHASE1":430,"PHASE2":432,"PHASE3":434,"PHASE4":436,"NA":438},{"trials":408,"activeCount":82,"soonestReadout":42},[409,419],{"nctId":65,"briefTitle":66,"status":109,"phases":410,"primaryCompletion":67,"completion":411,"start":412,"enrollment":413,"conditions":414,"interventions":418},[74],"2030-12","2025-02-01",80,[415,416,28,417],"Hypoxic-Ischaemic Encephalopathy","Neonatal Encephalopathy","Neonatal Hypoxic Ischemic Encephalopathy",[43],{"nctId":40,"briefTitle":41,"status":109,"phases":420,"primaryCompletion":42,"completion":421,"start":422,"enrollment":423,"conditions":424,"interventions":429},[74],"2030-01-01","2024-11-22",10,[425,426,416,417,427,28,428],"Hypoxic Ischaemic Encephalopathy (HIE)","Hypoxic Ischemic Encephalopathy of Newborn","Brain Injury","Perinatal Asphyxia , Moderate to Severe HIE",[43],{"trials":431,"activeCount":86},[],{"trials":433,"activeCount":86},[],{"trials":435,"activeCount":86},[],{"trials":437,"activeCount":86},[],{"trials":439,"activeCount":86},[],{"intervention":38,"totalTrials":117,"cells":441},{"EARLY_PHASE1":442,"PHASE1":444,"PHASE2":446,"PHASE3":448,"PHASE4":450,"NA":452},{"trials":443,"activeCount":86},[],{"trials":445,"activeCount":86},[],{"trials":447,"activeCount":86},[],{"trials":449,"activeCount":86},[],{"trials":451,"activeCount":86},[],{"trials":453,"activeCount":117,"soonestReadout":37},[454],{"nctId":35,"briefTitle":36,"status":355,"phases":455,"primaryCompletion":37,"completion":456,"start":457,"enrollment":413,"conditions":458,"interventions":460},[79],"2025-12-31","2023-09-01",[459,19],"Vasodilation",[38],{"intervention":462,"totalTrials":117,"cells":463},"Acenocoumarol",{"EARLY_PHASE1":464,"PHASE1":466,"PHASE2":468,"PHASE3":470,"PHASE4":472,"NA":488},{"trials":465,"activeCount":86},[],{"trials":467,"activeCount":86},[],{"trials":469,"activeCount":86},[],{"trials":471,"activeCount":86},[],{"trials":473,"activeCount":86},[474],{"nctId":475,"briefTitle":476,"status":477,"phases":478,"primaryCompletion":479,"completion":480,"start":481,"enrollment":482,"conditions":483,"interventions":487},"NCT02826200","Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography (RETORIC)","UNKNOWN",[78],"2018-07","2019-01","2016-07",200,[484,485,486],"Prosthetic Cardiac Valve Thrombosis","Cerebrovascular Accident","Prosthetic Valve Malfunction",[462],{"trials":489,"activeCount":86},[],{"intervention":491,"totalTrials":117,"cells":492},"Chlorhexidine mouthwash",{"EARLY_PHASE1":493,"PHASE1":495,"PHASE2":497,"PHASE3":499,"PHASE4":501,"NA":515},{"trials":494,"activeCount":86},[],{"trials":496,"activeCount":86},[],{"trials":498,"activeCount":86},[],{"trials":500,"activeCount":86},[],{"trials":502,"activeCount":86},[503],{"nctId":504,"briefTitle":505,"status":96,"phases":506,"primaryCompletion":507,"completion":508,"start":509,"enrollment":510,"conditions":511,"interventions":514},"NCT05178823","Short- and Long Term Antibacterial Effects of a Single Rinse With Different Mouthwashes: a Randomized Clinical Trial",[78],"2019-09-01","2020-09-01","2017-06-01",171,[512,513],"Gingival Diseases","Caries",[491],{"trials":516,"activeCount":86},[],{"intervention":518,"totalTrials":117,"cells":519},"Inspra",{"EARLY_PHASE1":520,"PHASE1":522,"PHASE2":524,"PHASE3":526,"PHASE4":528,"NA":540},{"trials":521,"activeCount":86},[],{"trials":523,"activeCount":86},[],{"trials":525,"activeCount":86},[],{"trials":527,"activeCount":86},[],{"trials":529,"activeCount":86},[530],{"nctId":531,"briefTitle":532,"status":96,"phases":533,"primaryCompletion":534,"completion":534,"start":535,"enrollment":536,"conditions":537,"interventions":539},"NCT02462499","Eplerenone Treatment for Chronic Central Serous Chorioretinopathy in Hungarian Population",[78],"2016-09","2014-06",28,[538],"Chronic Central Serous Chorioretinopathy",[518],{"trials":541,"activeCount":86},[],{"intervention":543,"totalTrials":17,"cells":544},"Cholecalciferol",{"EARLY_PHASE1":545,"PHASE1":547,"PHASE2":549,"PHASE3":562,"PHASE4":594,"NA":596},{"trials":546,"activeCount":86},[],{"trials":548,"activeCount":86},[],{"trials":550,"activeCount":86},[551],{"nctId":552,"briefTitle":553,"status":96,"phases":554,"primaryCompletion":555,"completion":556,"start":557,"enrollment":558,"conditions":559,"interventions":561},"NCT04840238","30000 IU Per Week Vitamin D Treatment in PCOS Patients",[76],"2022-02","2022-12","2016-12-08",115,[560,23],"Polycystic Ovary Syndrome",[543],{"trials":563,"activeCount":86},[564,573,585],{"nctId":565,"briefTitle":566,"status":96,"phases":567,"primaryCompletion":568,"completion":568,"start":569,"enrollment":570,"conditions":571,"interventions":572},"NCT02069990","Controlled, Randomized, Four-arm Comparative, Open Label, Multi-centric Clinical Trial to Compare the Efficacy and Safety Parameters of the Once-a-week or Once-a-month Administered 7000 IU, or 30000 IU Vitamin D (Cholecalciferol) to a 1000 IU Dosage Applied Daily in Vitamin D Deficient Patients",[77],"2013-09","2013-03",89,[23],[543],{"nctId":574,"briefTitle":575,"status":576,"phases":577,"primaryCompletion":578,"completion":578,"start":579,"enrollment":580,"conditions":581,"interventions":583},"NCT01518959","The Effect of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases","TERMINATED",[77],"2017-01","2012-01",31,[582],"Chronic Lymphoid Leukemia",[543,584],"oleum neutralicum",{"nctId":586,"briefTitle":587,"status":96,"phases":588,"primaryCompletion":589,"completion":589,"start":590,"enrollment":591,"conditions":592,"interventions":593},"NCT04476511","The Efficacy and the Safety of Vitamin D3 30,000 IU for Loading Dose Schedules",[77],"2021-12-15","2018-09-05",75,[23],[543],{"trials":595,"activeCount":86},[],{"trials":597,"activeCount":86},[],{"intervention":599,"totalTrials":117,"cells":600},"Vigantol oil and MCT oil",{"EARLY_PHASE1":601,"PHASE1":603,"PHASE2":605,"PHASE3":607,"PHASE4":620,"NA":622},{"trials":602,"activeCount":86},[],{"trials":604,"activeCount":86},[],{"trials":606,"activeCount":86},[],{"trials":608,"activeCount":86},[609],{"nctId":610,"briefTitle":611,"status":576,"phases":612,"primaryCompletion":613,"completion":614,"start":615,"enrollment":616,"conditions":617,"interventions":619},"NCT01535196","Vitamine D Treatment in Chronic Heart Failure",[77],"2017-05","2017-09","2012-12",8,[30,618],"Vitamin D Adverse Reaction",[599],{"trials":621,"activeCount":86},[],{"trials":623,"activeCount":86},[],{"intervention":625,"totalTrials":117,"cells":626},"Tolperisone Hydrochloride",{"EARLY_PHASE1":627,"PHASE1":629,"PHASE2":631,"PHASE3":633,"PHASE4":646,"NA":648},{"trials":628,"activeCount":86},[],{"trials":630,"activeCount":86},[],{"trials":632,"activeCount":86},[],{"trials":634,"activeCount":86},[635],{"nctId":636,"briefTitle":637,"status":477,"phases":638,"primaryCompletion":639,"completion":640,"start":641,"enrollment":642,"conditions":643,"interventions":645},"NCT05544656","The Prognostic Value of Biomarkers and the Effect of Tolperisone in Acute Low Back Pain and Sciatic Pain \"BETA\"",[77],"2023-12-31","2024-06-30","2019-12-13",150,[644],"Low Back Pain",[625],{"trials":647,"activeCount":86},[],{"trials":649,"activeCount":86},[],{"intervention":584,"totalTrials":117,"cells":651},{"EARLY_PHASE1":652,"PHASE1":654,"PHASE2":656,"PHASE3":658,"PHASE4":664,"NA":666},{"trials":653,"activeCount":86},[],{"trials":655,"activeCount":86},[],{"trials":657,"activeCount":86},[],{"trials":659,"activeCount":86},[660],{"nctId":574,"briefTitle":575,"status":576,"phases":661,"primaryCompletion":578,"completion":578,"start":579,"enrollment":580,"conditions":662,"interventions":663},[77],[582],[543,584],{"trials":665,"activeCount":86},[],{"trials":667,"activeCount":86},[],{"intervention":669,"totalTrials":117,"cells":670},"Ascorbic Acid",{"EARLY_PHASE1":671,"PHASE1":673,"PHASE2":684,"PHASE3":686,"PHASE4":688,"NA":690},{"trials":672,"activeCount":86},[],{"trials":674,"activeCount":86},[675],{"nctId":676,"briefTitle":677,"status":96,"phases":678,"primaryCompletion":679,"completion":679,"start":680,"enrollment":101,"conditions":681,"interventions":683},"NCT02606773","\"Novo C Plus\" Vitamin C Containing Dietary Supplement Bioavailability in Healthy Subjects",[75],"2015-09","2015-06",[682],"Vitamin C Deficiency",[669],{"trials":685,"activeCount":86},[],{"trials":687,"activeCount":86},[],{"trials":689,"activeCount":86},[],{"trials":691,"activeCount":86},[],{"intervention":693,"totalTrials":82,"cells":694},"nitroglycerin",{"EARLY_PHASE1":695,"PHASE1":697,"PHASE2":699,"PHASE3":701,"PHASE4":703,"NA":705},{"trials":696,"activeCount":86},[],{"trials":698,"activeCount":86},[],{"trials":700,"activeCount":86},[],{"trials":702,"activeCount":86},[],{"trials":704,"activeCount":86},[],{"trials":706,"activeCount":86},[707,718],{"nctId":708,"briefTitle":709,"status":96,"phases":710,"primaryCompletion":711,"completion":712,"start":713,"enrollment":714,"conditions":715,"interventions":717},"NCT03605095","Evidence of Spreading Vasodilation in Human Gingiva",[79],"2018-08-30","2018-09-10","2018-07-25",40,[716,459,19],"Nitric Oxide",[693],{"nctId":719,"briefTitle":720,"status":96,"phases":721,"primaryCompletion":722,"completion":723,"start":724,"enrollment":725,"conditions":726,"interventions":728},"NCT04918563","Endothelium Dependent and Non-dependent Vasodilatation in Human Gingiva",[79],"2021-04-15","2021-05-15","2020-09-15",24,[727,19],"Vasodilatation",[729,730],"Nitroglycerin","Acetylcholine",{"intervention":732,"totalTrials":117,"cells":733},"Ceftolozane\u002Ftazobactam",{"EARLY_PHASE1":734,"PHASE1":736,"PHASE2":738,"PHASE3":740,"PHASE4":742,"NA":744},{"trials":735,"activeCount":86},[],{"trials":737,"activeCount":86},[],{"trials":739,"activeCount":86},[],{"trials":741,"activeCount":86},[],{"trials":743,"activeCount":86},[],{"trials":745,"activeCount":86},[746],{"nctId":747,"briefTitle":748,"status":477,"phases":749,"primaryCompletion":750,"completion":750,"start":751,"enrollment":752,"conditions":753,"interventions":756},"NCT04352855","Ceftolozane-tazobactam for the Treatment of Respiratory Infections Due to Extensively Drug-resistant Pseudomonas Aeruginosa Among Critically Ill Patients: a Retrospective Study.",[],"2020-05-19","2018-01-18",55,[754,755],"Ventilator Associated Pneumonia","Antibiotic Resistant Infection",[732],{"intervention":758,"totalTrials":117,"cells":759},"travoprost 0.003%",{"EARLY_PHASE1":760,"PHASE1":762,"PHASE2":764,"PHASE3":766,"PHASE4":768,"NA":770},{"trials":761,"activeCount":86},[],{"trials":763,"activeCount":86},[],{"trials":765,"activeCount":86},[],{"trials":767,"activeCount":86},[],{"trials":769,"activeCount":86},[],{"trials":771,"activeCount":86},[772],{"nctId":773,"briefTitle":774,"status":96,"phases":775,"primaryCompletion":776,"completion":776,"start":777,"enrollment":778,"conditions":779,"interventions":782},"NCT01491867","Continuous Intraocular Pressure (IOP) Measurement and Ability to Detect Treatment Effect",[79],"2012-10","2011-12",9,[780,781],"Glaucoma","Ocular Hypertension",[758],{"intervention":784,"totalTrials":117,"cells":785},"Remdesivir",{"EARLY_PHASE1":786,"PHASE1":788,"PHASE2":790,"PHASE3":792,"PHASE4":794,"NA":796},{"trials":787,"activeCount":86},[],{"trials":789,"activeCount":86},[],{"trials":791,"activeCount":86},[],{"trials":793,"activeCount":86},[],{"trials":795,"activeCount":86},[],{"trials":797,"activeCount":86},[798],{"nctId":799,"briefTitle":800,"status":96,"phases":801,"primaryCompletion":802,"completion":802,"start":803,"enrollment":804,"conditions":805,"interventions":808},"NCT04854837","Safety of Remdesivir Treatment in COVID-19 Patients Requiring Hemodialysis",[],"2022-09-30","2021-04-12",45,[806,807],"Covid19","End Stage Renal Failure on Dialysis",[784],{"intervention":810,"totalTrials":117,"cells":811},"Epinephrine",{"EARLY_PHASE1":812,"PHASE1":814,"PHASE2":816,"PHASE3":818,"PHASE4":820,"NA":822},{"trials":813,"activeCount":86},[],{"trials":815,"activeCount":86},[],{"trials":817,"activeCount":86},[],{"trials":819,"activeCount":86},[],{"trials":821,"activeCount":86},[],{"trials":823,"activeCount":86},[824],{"nctId":825,"briefTitle":826,"status":96,"phases":827,"primaryCompletion":828,"completion":829,"start":830,"enrollment":831,"conditions":832,"interventions":835},"NCT04131283","Evidence of Spreading Vasoconstriction in Human Gingiva",[79],"2019-12-01","2020-01-01","2019-05-01",29,[833,19,834],"Vasoconstriction","Dental and Gingival Conditions",[810],{"intervention":837,"totalTrials":117,"cells":838},"standard dermatological care",{"EARLY_PHASE1":839,"PHASE1":841,"PHASE2":843,"PHASE3":845,"PHASE4":847,"NA":849},{"trials":840,"activeCount":86},[],{"trials":842,"activeCount":86},[],{"trials":844,"activeCount":86},[],{"trials":846,"activeCount":86},[],{"trials":848,"activeCount":86},[],{"trials":850,"activeCount":86},[851],{"nctId":852,"briefTitle":853,"status":96,"phases":854,"primaryCompletion":855,"completion":855,"start":856,"enrollment":101,"conditions":857,"interventions":859},"NCT07599878","Adjunctive Group Psychotherapy for Moderate-to-Severe Atopic Dermatitis: A Pilot Feasibility Study Comparing Two Interventions",[79],"2023-07-10","2022-09-05",[858],"Atopic Dermatitis",[837],{"intervention":861,"totalTrials":117,"cells":862},"Optimal medical therapy",{"EARLY_PHASE1":863,"PHASE1":865,"PHASE2":867,"PHASE3":869,"PHASE4":871,"NA":873},{"trials":864,"activeCount":86},[],{"trials":866,"activeCount":86},[],{"trials":868,"activeCount":86},[],{"trials":870,"activeCount":86},[],{"trials":872,"activeCount":86},[],{"trials":874,"activeCount":86},[875],{"nctId":876,"briefTitle":877,"status":477,"phases":878,"primaryCompletion":879,"completion":879,"start":880,"enrollment":881,"conditions":882,"interventions":884},"NCT03840499","The Role of Willingness of Participation in Cardiology Trials on the Survival of Patients",[],"2022-12-31","2018-10-01",400,[883,30],"Myocardial Infarction",[861],{"intervention":730,"totalTrials":117,"cells":886},{"EARLY_PHASE1":887,"PHASE1":889,"PHASE2":891,"PHASE3":893,"PHASE4":895,"NA":897},{"trials":888,"activeCount":86},[],{"trials":890,"activeCount":86},[],{"trials":892,"activeCount":86},[],{"trials":894,"activeCount":86},[],{"trials":896,"activeCount":86},[],{"trials":898,"activeCount":86},[899],{"nctId":719,"briefTitle":720,"status":96,"phases":900,"primaryCompletion":722,"completion":723,"start":724,"enrollment":725,"conditions":901,"interventions":902},[79],[727,19],[729,730],{"intervention":904,"totalTrials":117,"cells":905},"Anti-VEGF",{"EARLY_PHASE1":906,"PHASE1":908,"PHASE2":910,"PHASE3":912,"PHASE4":914,"NA":916},{"trials":907,"activeCount":86},[],{"trials":909,"activeCount":86},[],{"trials":911,"activeCount":86},[],{"trials":913,"activeCount":86},[],{"trials":915,"activeCount":86},[],{"trials":917,"activeCount":86},[918],{"nctId":919,"briefTitle":920,"status":96,"phases":921,"primaryCompletion":922,"completion":923,"start":924,"enrollment":9,"conditions":925,"interventions":927},"NCT05678517","Seven-year Outcomes Following Intensive Anti-VEGF Therapy in Wet AMD",[],"2017-12-31","2022-12-06","2010-01-01",[926],"Age-Related Macular Degeneration",[904],{"intervention":929,"totalTrials":117,"cells":930},"Alteplase Injectable Product",{"EARLY_PHASE1":931,"PHASE1":933,"PHASE2":935,"PHASE3":937,"PHASE4":939,"NA":941},{"trials":932,"activeCount":86},[],{"trials":934,"activeCount":86},[],{"trials":936,"activeCount":86},[],{"trials":938,"activeCount":86},[],{"trials":940,"activeCount":86},[],{"trials":942,"activeCount":86},[943],{"nctId":944,"briefTitle":945,"status":96,"phases":946,"primaryCompletion":947,"completion":947,"start":948,"enrollment":949,"conditions":950,"interventions":954},"NCT06667882","Safe Delivery of Thrombolytic Treatment for Pulmonary Embolism Using ClotPro® Viscoelastic Tests",[79],"2024-10-24","2021-12-17",33,[951,952,953],"Pulmonary Embolism Subacute Massive","Complication of Treatment","Fibrinolysis; Hemorrhage",[929],{"intervention":956,"totalTrials":117,"cells":957},"twice-daily dosage with 0.5% cyclosporine-A eyedrops",{"EARLY_PHASE1":958,"PHASE1":960,"PHASE2":962,"PHASE3":964,"PHASE4":966,"NA":968},{"trials":959,"activeCount":86},[],{"trials":961,"activeCount":86},[],{"trials":963,"activeCount":86},[],{"trials":965,"activeCount":86},[],{"trials":967,"activeCount":86},[],{"trials":969,"activeCount":86},[970],{"nctId":971,"briefTitle":972,"status":477,"phases":973,"conditions":974,"interventions":976},"NCT00433277","Autoimmunity in Retinitis Pigmentosa",[79],[975],"Retinitis Pigmentosa",[956]]